Here, using samples from a randomized controlled trial, the authors show that a multiplex immunoassay (MultiCruzi), paired with statistical analysis, can predict early treatment efficacy in adult Chagas patients, suggesting that MultiCruzi could serve as an endpoint in future clinical trials.
- Ursula Saade
- Jasper de Boer
- Maan Zrein
